哮喘大鼠肾上腺髓质嗜铬细胞表型转化与神经生长因子表达水平初探

目的观察支气管哮喘状态下大鼠肾上腺髓质嗜铬细胞(AMCC)形态和功能的改变以及神经生长因子(NGF)在肾上腺髓质嗜铬细胞中的表达,探讨肾上腺髓质嗜铬细胞与支气管哮喘的关系。方法2005年10月至2006年3月,在中南大学湘雅医院呼吸内科将雄性SD大鼠16只,随机分为对照组和哮喘组,每组8只。哮喘组以鸡卵清蛋白(OVA)致敏和激发哮喘,对照组以生理盐水代替OVA进行致敏和激发。光镜和电镜下观察2组大鼠肾上腺髓质嗜铬细胞的组织结构和超微结构改变,免疫组织化学结合显微图像分析观察肾上腺髓质嗜铬细胞中NGF的表达变化,酶联免疫吸附法(ELISA)检测血清中肾上腺素和去甲肾上腺素的变化。结果HE染色光镜下可见哮喘组大鼠肾上腺髓质嗜铬细胞不同程度的空泡变性样改变,脂质增多,少数可见纤维样物质伸向皮质。电镜下哮喘组大鼠髓质嗜铬细胞线粒体丰富,脂质增多,嗜铬颗粒浓度降低,并且部分出现核膜皱缩现象。与对照组相比,哮喘大鼠NGF免疫阳性反应在肾上腺髓质嗜铬细胞明显上调(P<0.05),ELISA示哮喘组大鼠肾上腺素水平明显低于对照组(P<0.05),去甲肾上腺素水平没有明显变化(P>0.05)。结论支气管哮喘时肾上腺髓质嗜铬细胞NGF的表达增高,增高的NGF可能使肾上腺髓质嗜铬细胞发生表型的转化导致肾上腺素合成与释放不足而参与哮喘的发生、发展。     

妊娠期支气管哮喘诱导子代大鼠肾上腺髓质嗜铬细胞表型转变

目前研究结果表明,支气管哮喘(简称哮喘)患者可能存在肾上腺素释放功能障碍,导致体内肾上腺素水平过低,造成难以有效缓解哮喘所致的支气管痉挛.这一病理生理现象的出现可能与下列机制存在密切关联:哮喘患者体内神经生长因子(nerve growth factor,NGF)表达过高,诱导肾上腺髓质嗜铬细胞发生神经元转变倾向,进而损伤嗜铬细胞的内分泌功能,使肾上腺素分泌减少.本研究中采用卵清白蛋白(OVA)致敏和激发的方法建立妊娠期哮喘大鼠模型,并用NGF及其抗体对模型进行干预,观察子代大鼠肾上腺髓质嗜铬细胞表型的转变情况.     

神经生长因子启动肾上腺髓质细胞功能冗余性致肾上腺素释放障碍的研究

目的 探讨神经生长因子(NGF)等对原代培养的肾上腺髓质嗜铬细胞生物行为学影响的发生机制.方法 采用单细胞消化法原代培养肾上腺髓质细胞,密度梯度离心和差速贴壁法分离和纯化肾上腺髓质细胞.相差显微镜、电镜观察外源性NGF、P物质(SP)作用下肾上腺髓质嗜铬细胞形态和超微结构的改变,酶联免疫吸附试验(ELISA)法检测培养上清液中肾上腺素和去甲肾上腺素浓度的变化.结果 NGF干预2 d后,相差显微镜下可见肾上腺髓质细胞膜表面渐渐长出长丝状突起.电镜下NGF干预后可见肾上腺髓质嗜铬细胞表面丰富的杵状和绒毛状突起,近细胞膜处可见小囊泡形成,细胞浆内线粒体丰富,结构较模糊,部分嵴丢失.ELISA检测发现经NGF干预后培养上清液中肾上腺素浓度较正常组明显降低(P＜0.05),去甲肾上腺素浓度没有明显改变.SP干预后肾上腺素和去甲肾上腺素浓度没有明显改变.结论 NGF通过启动肾上腺髓质细胞功能冗余性使其表型和功能发生改变致肾上腺素合成和释放障碍.     

神经生长因子、白血病抑制因子调控支气管哮喘大鼠神经源性炎症机制的研究

目的研究神经生长因子(NGF)、白血病抑制因子(LIF)调控支气管哮喘(简称哮喘)大鼠气道神经源性炎症的机制,寻求治疗哮喘的新靶点。方法成年清洁级雄性SD大鼠36只,按随机数字表法分为对照组、哮喘组和抗NGF组,每组12只。采用免疫组织化学和原位杂交技术观察哮喘大鼠肺组织、C7～T5背根神经节内NGF、LIF、P物质(SP)的表达状态及抗NGF干预对其表达的影响。结果(1)哮喘组大鼠肺组织NGF、LIF蛋白及其mRNA的平均灰度值分别为157±7、138±8、156±6、141±10,对照组分别为183±7、190±7、187±7、181±8,抗NGF干预组分别为177±6、169±9、178±7、172±9,三组比较差异有统计学意义(t分别=19.40、15.80、0.38、14.79,P均<0.01);(2)哮喘组大鼠C7～T5背根神经节NGF、LIF、SP蛋白及SPmRNA的灰度值分别为136±8、148±6、140±8、128±8,对照组分别为185±7、187±8、174±7、180±8,抗NGF干预组分别为164±6、170±8、163±9、157±7,三组比较差异有统计学意义(t分别=29.50、22.65、23.12、28.71,P均<0.01)。结论促进背根神经节细胞合成和释放SP可能是NGF、LIF参与哮喘气道神经源性炎症形成的机制之一,抗NGF干预能够有效地将其抑制。     

系统性红斑狼疮患者血清中B淋巴细胞刺激因子的检测

目的检测系统性红斑狼疮(SLE)患者血清B淋巴细胞刺激因子(BLyS)水平,并探讨其在SLE发病中的意义。方法采用双抗体夹心酶联免疫吸附试验(ELISA)法检测血清BLyS水平。结果①SLE患者血清BLyS[(9.6±2.3)ng/ml]显著高于正常人对照组[(4.0±1.5)ng/ml]。②SLE患者中,血清BLyS水平活动组[(11.1±2.2)ng/ml]高于非活动组[(8.1±1.2)ng/ml],抗dsDNA抗体阳性组[(10.9±2.2)ng/ml]高于抗dsDNA抗体阴性组[(8.1±1.4)ng/ml],高IgG组[(10.8±2.4)ng/ml]高于非高IgG组[(8.3±1.3)ng/ml],低C3组[(10.2±2.5)ng/ml]高于非低C3组[(8.3±1.3)ng/ml],低C4组[(10.1±2.3)ng/ml]高于非低C4组[(7.6±0.7)ng/ml],低血小板计数组[(10.7±2.7)ng/ml]高于非低血小板计数组[(8.8±1.7)ng/ml]。③SLE患者血清BLyS水平与SLE疾病活动指数(SLEDAI)(r=0.56,t=15.89,P<0.01)、IgG(r=0.33,t=4.20,P<0.05)呈正相关;与C4(r=-0.47,t=10.04,P<0.01)、血小板计数(r=-0.53,t=13.85,P<0.01)呈负相关。结论BLyS可能参与SLE的发病。     

抗神经生长因子干预对哮喘大鼠肺神经生长因子表达的影响

目的探讨抗神经生长因子(NGF)干预对哮喘大鼠肺内NGF表达的影响。方法通过鸡卵蛋白致敏激发建立哮喘模型,48只SD大鼠按随机数字法分为对照组、哮喘组和抗NGF干预组,每组16只。苏木素-伊红(HE)染色观察气道病理改变;用免疫组织化学方法检测哮喘大鼠肺内NGF表达水平。结果 NGF的表达与呼吸道平滑肌厚度呈正相关。哮喘组呼吸道平滑肌厚度及NGF的表达均高于对照组和抗NGF干预组(P0.05);抗NGF干预组NGF表达高于对照组(P0.05)。结论在实验哮喘大鼠中,肺内NGF表达水平明显增高,抗NGF干预后肺内NGF表达水平有所减少。     

白细胞介素5和嗜酸粒细胞趋化因子在支气管哮喘大鼠肺和骨髓信号传导中的作用

目的探讨支气管哮喘(简称哮喘)大鼠模型中白细胞介素5(IL-5)和嗜酸粒细胞趋化因子(eotaxin)是否参与肺和骨髓间信号传导,观察不同干预措施的影响。方法清洁级雄性Wistar大鼠40只,按随机数字表法分为正常对照组和哮喘组,每组20只。用卵白蛋白(OVA)致敏和激发制作哮喘模型,于激发后30 min及6、12、24、48 h处死大鼠,分别取外周血涂片、骨髓细胞涂片。肺组织以10％甲醛固定做石蜡切片。将血涂片、骨髓涂片、肺组织切片行苏木精-伊红(HE)染色,观察细胞总数和嗜酸粒细胞(EOS)比例。取不同时间点肺组织匀浆,用酶联免疫吸附测定(ELISA)法测定肺组织匀浆IL-5和eotaxin浓度。将不同时间点的肺组织匀浆与正常对照组和哮喘组大鼠骨髓细胞共同孵育,并分别加入地塞米松(DXM)、半乳凝素3(Galectin-3)、孟鲁司特钠、抗IL-5抗体进行干预,采用抗IL-5、抗IL-SRα、抗eotaxin、抗CD34和抗CC趋化因子受体3(CCR3)多克隆抗体进行免疫组化染色,检测两组骨髓细胞中EOS计数和IL-5+细胞、IL-5Rα+细胞、CCR3+细胞、eotaxin+细胞、CD34+细胞的百分比。结果哮喘大鼠外周血、骨髓、肺组织中EOS数分别为0．020 0±0．002 0、0．023±0．003、0．025 0±0．009 0,正常对照组分别为0．010 0±0．003 0、0．009±0．003、0．009 0±0．002 0,两组比较差异有统计学意义(t值分别为2．547、2．718、2．718,P均<0．05);哮喘大鼠肺组织匀浆于激发6 h的IL-5为(89．3±2．4)pg/ml,12 h的eotaxin水平为(4．9±0．5)pg／ml,48 h均回到基线[(1．45±0．23) pg／ml]水平;除30 min外,各时间点哮喘大鼠肺组织匀浆均能诱导正常对照组或哮喘组大鼠骨髓细胞中CD34+、EOS、IL-5+、IL-SRα+、CCR3+、eotaxin+细胞表达增加,Galectin-3干预哮喘大鼠骨髓细胞后,骨髓EOS、IL-5+、IL-5Rα+、CCR3+、eotaxin+和CD34+细胞表达减少(分别为0．021±0．005、0．074±0．007、0．138±0．014、0．067±0．010、0．040±0．005、0．087±0．012)。结论IL-5 mRNA转录选择性抑制物(Galectin-3)能抑制EOS炎症,有可能成为一种特异性的抗哮喘药物。     

慢性间断缺氧小鼠缺氧诱导因子1α的研究

目的　探索睡眠呼吸暂停综合征(SAS)的慢性间断性缺氧(CIH)对心血管损害的可能机制。方法　制作CIH小鼠模型。将30只ICR小鼠均分为实验组、空气模拟对照组及空白对照组。免疫组织化学方法检测实验小鼠心肌细胞缺氧诱导因子1α(HIF1α)及诱导型一氧化氮合成酶(NOS2)的表达。酶联免疫吸附测定(ELISA)方法检测小鼠血浆血管内皮生长因子(VEGF)及内皮素1(ET1)的浓度。结果　实验组心肌细胞HIF1α表达高于空白对照组(t=354,P<005)及空气模拟对照组(t=292,P<005);空白对照组HIF1α表达与空气模拟对照组比较差异无统计学意义(P>005)。实验组血浆VEGF浓度[(957±141)ng/ml]高于空白对照组[(810±062)ng/ml,q=427,P<005]及空气模拟对照组[(832±099)ng/ml,q=364,P<005];空白对照组血浆VEGF浓度与空气模拟对照组比较差异无统计学意义(P>005)。实验组血浆ET1浓度[(331±081)ng/ml]高于空白对照组[(250±072)ng/ml,q=364,P<005];空气模拟对照组血浆ET1浓度[(269±043)ng/ml]与实验组及空白对照组[(331±081)、(250±072)ng/ml]比较差异均无统计学意义(P均>005)。小鼠心肌细胞NOS2表达在各组间比较差异均无统计学意义(P均>005)。结论　CIH可引起小鼠HIF1α表达增加,并可促进HIF1α目的基因产物VEGF、ET1的表达。这可能     

血清基质金属蛋白酶-9检测与系统性红斑狼疮活动性的关系

目的探讨血清基质金属蛋白酶-9(MMP-9)与系统性红斑狼疮(SLE)活动程度的关系和意义。方法采用双抗体夹心酶联免疫吸附测定法,检测30名健康人和36例SLE患者血清MMP-9水平,以分析其与SLE活动性变化关系。结果SLE患者血清MMP-9水平[(108±113)ng/ml]明显低于正常对照组[(352±115)ng/ml],P<0.001;糖皮质激素治疗后血清MMP-9水平[(246±196)ng/ml]与治疗前水平[(114±92)ng/ml]相比,差异有显著性意义(P<0.05);SLE患者活动期血清MMP-9水平[(72±66)ng/ml]低于非活动期[(166±146)ng/ml],P<0.05;SLEDAI>8分组[(80±72)ng/ml]低于SLEDAI≤8分组[(152±150)ng/ml],P<0.05;蛋白尿组[(82±20)ng/ml]低于非蛋白尿组[(152±43)ng/ml],P<0.05;关节炎组[(103±126)ng/ml]与非关节炎组[(117±89)ng/ml]之间差异无显著性,P>0.05。结论MMP-9可能与SLE的发病相关,血清MMP-9可作为反映SLE活动程度、肾脏损害及疾病进展或改善的一项指标。     

维A酸对大鼠实验性阻塞性肺气肿的预防作用及其机制探讨

目的　观察维A酸 (RA)对慢性阻塞性肺气肿大鼠的预防效果并对其机制进行探讨。方法　Wistar大鼠 36只随机分为三组 ,正常对照组、模型组和用药组 ,每组 12只 ,模型组和用药组大鼠进行熏香烟实验 ,用药组同时用RA进行预防。吸烟实验结束后 ,观察各组大鼠的病理及肺功能情况 ,酶联免疫吸附试验 (ELISA)检测基质金属蛋白酶 2 (MMP 2 )和MMP 9的活性变化 ,免疫组化法观察MMP 2和MMP 9以及增殖细胞核抗原 (PCNA)的表达情况。结果　模型组肺功能指标 0 3秒用力呼气容积 (FEV0 3 )、FEV0 3 /FVC(用力肺活量 )和功能残气量 (FRC)分别为 [(5 1± 0 4 )ml、(71± 10 )ml/s、(7 2± 2 2 )ml],与正常对照组 [(6 0± 0 3)ml、(87± 3)ml/s、(2 9± 1 1)ml]比较 ,差异有显著性(P <0 0 1) ;模型组MMP 2和MMP 9的活性分别为 [(1 0 6± 0 2 3)ng/ml、(0 96 0± 0 2 30 )ng/ml],其表达与正常对照组 [(0 5 3± 0 17)ng/ml、(0 30 0± 0 0 90 )ng/ml]比较 ,差异有显著性 (P <0 0 1)。用药组肺功能指标分别为 [(5 2± 0 4 )ml、(81± 5 )ml/s、(6 1± 2 7)ml/s],与模型组比较差异有显著性 (P <0 0 5 ) ;用药组MMP 2和MMP 9的活性 [(0 83± 0 2 3)ng/ml、(0 5 70± 0 0 10 )ng/ml]和表达与模型组比     

Effects of dopamine on the adrenal gland of Podarcis sicula (Reptilia, Lacertidae)

The effects of dopamine administration on the adrenal gland of a lizard, Podarcis sicula, are described. Dopamine (0.7mg/100g body wt/day for 4 consecutive days) raised plasma ACTH and corticosterone levels (ACTH: from the basal level of 4.40+/-0.05-7.30+/-0.08pg/ml 24h after the fourth dopamine injection; corticosterone: from 3.59+/-0.03ng/ml in untreated lizards to 7.40+/-0.05ng/ml 24h after the fourth dopamine injection), showing a stimulatory effect on the pituitary-interrenal axis activity. In the chromaffin tissue dopamine apparently enhanced the activity of PNMT enzyme; in fact a strong raise in the number of adrenaline cells and a decrease in the number of noradrenaline cells were observed, decreasing the numeric NA/A cell ratio, from 1.4/1 of control specimens to 0.5/1 24h after the fourth dopamine injection. At EM level, chromaffin cells contained both NA and A granules, as well as very clear granules (CG); CG granules showed granular elements ranging between 340 and 347A in diameter. These cells might be the morphological expression of a process of catecholamine resynthesis, due to a possible increase in catecholamine release, following exposure to dopamine.     

Anti-nerve growth factor antibody improves airway hyperresponsiveness by down-regulating RhoA

Background: The pathogenesis of asthma is complex and continues to be considered as a challenging subject. Some studies have shown that nerve growth factor (NGF) participates in the pathogenesis of asthma, but the mechanism of airway contraction caused by NGF is still unclear. Objective: Our aim was to discuss the effect of anti-NGF antibody on RhoA expression, and further explore the role of NGF in airway hyperresponsiveness (AHR). Methods: Thirty female BALB/c mice were divided into three groups randomly: control group (group C, n = 10), asthma group (group A, n = 10) and anti-NGF antibody intervention group (group N, n = 10). The asthmatic mice were stimulated by OVA suspension, the intervention mice were given nasal instillation of anti-NGF antibody before the stimulation. Airway responsiveness, eosinophils, IL-13, IFN-γ were measured. The protein expression and mRNA level of NGF and RhoA were detected by immunohistochemical and Real Time-PCR (RT-PCR) analyses. Results: Airway responsiveness, eosinophils and IL-13 levels in group A were significantly increased compare with the other groups, and significantly decreased in group N than those in group A. IFN-γ level was significantly reduced in group A and increased in group N. Immunohistochemistry and RT-PCR analyses showed that the protein expression and mRNA level of NGF and RhoA were significantly increased in group A and significantly decreased in group N. Conclusion: NGF participates in the pathogenesis of asthma in mice. Anti-NGF antibody can inhibit airway inflammation and alleviate AHR by down-regulating the protein expression and mRNA level of RhoA.     

Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma.

Nerve growth factor (NGF) serum levels were measured in 49 patients with asthma and/or rhinoconjunctivitis and/or urticaria-angioedema. Clinical and biochemical parameters, such as bronchial reactivity, total and specific serum IgE levels, and circulating eosinophil cationic protein levels, were evaluated in relation to NGF values in asthma patients. NGF was significantly increased in the 42 allergic (skin-test- or radioallergosorbent-test-positive) subjects (49.7 +/- 28.8 pg/ml) versus the 18 matched controls (3.8 +/- 1.7 pg/ml; P < 0.001). NGF levels in allergic patients with asthma, rhinoconjunctivitis, and urticaria-angioedema were 132.1 +/- 90.8, 17.6 +/- 6.1, and 7.6 +/- 1.8 pg/ml (P < 0.001, P < 0.002, and P < 0.05 versus controls), respectively. Patients with more than one allergic disease had higher NGF serum values than those with a single disease. When asthma patients were considered as a group, NGF serum values (87.6 +/- 59.8 pg/ml) were still significantly higher than those of control groups (P < 0.001), but allergic asthma patients had elevated NGF serum levels compared with nonallergic asthma patients (132.1 +/- 90.8 versus 4.9 +/- 2.9 pg/ml; P < 0.001). NGF serum levels correlate to total IgE serum values (rho = 0.43; P < 0.02). The highest NGF values were found in patients with severe allergic asthma, a high degree of bronchial hyperreactivity, and high total IgE and eosinophil cationic protein serum levels. This study represents the first observation (that we know of) that NGF is increased in human allergic inflammatory diseases and asthma.     

实验性支气管哮喘豚鼠肺和内脏感觉传入系统蛋白激酶C的表达及神经生长因子的调节作用

目的探讨支气管哮喘(简称哮喘)豚鼠肺及内脏感觉传入系统(C7～T5脊神经节及对应的脊髓后角)蛋白激酶C(PKC)的表达及神经生长因子(NGF)的调节作用。方法40只豚鼠按随机数字表法分为4组生理盐水对照组(A组)8只、单纯致敏对照组(B组)8只、哮喘组(C组)12只和NGF抗体组(D组)12只。用免疫组织化学方法检测各组豚鼠C7～T5脊神经节和对应的脊髓后角PKC的免疫反应变化;采用Westernblot方法分别检测各组豚鼠肺组织、C7～T5脊神经节和对应的脊髓后角NGF与PKC的表达;采用LuzexF实时图像分析系统和凝胶成像分析系统分别对以上结果进行图像分析。结果(1)免疫组织化学A、B组豚鼠C7～T5脊神经节和对应的脊髓后角PKC的平均吸光度(A)值分别为0.102±0.009、0.113±0.009、0.106±0.005、0.116±0.007,二者比较差异无统计学意义(P>0.05)。C组豚鼠C7～T5脊神经节和对应的脊髓后角PKC的A值分别为0.215±0.014、0.176±0.010,C组与A组比较差异有统计学意义(P<0.01)。D组豚鼠C7～T5脊神经节和对应的脊髓后角PKC的A值分别为0.140±0.008、0.130±0.011,D组与C组比较差异有统计学意义(P<0.01)。(2)Westernblot蛋白印迹C组肺组织、C7～T5脊神经节神经元及相应脊髓节段PKC蛋白表达量(其A相对值分别为1.51±0.01、1.40±0.03、2.22±0.02)与A组(其A相对值分别为0.51±0.02、0.43±0.01、0.92±0.02)和B组比较均明显增加,而D组PKC蛋白表达量(其A相对值分别为0.80±0.03、0.83±0.01、1.12±0.02)明显低于C组。结论PKC可能参与哮喘的发病过程,而NGF可上调哮喘豚鼠PKC的表达。     

白细胞介素12重组腺病毒气道内应用对哮喘豚鼠治疗作用的研究

目的　探讨激发前气道内应用白细胞介素 12 (IL 12 )重组腺病毒对过敏性气道高反应的调节作用。方法　以C5 7BL/ 6小鼠经鸡卵蛋白 (OVA)免疫建立哮喘模型 ,实验分 6组 ,每组 6只。激发前气管内单次使用IL 12重组腺病毒 (10 8pfu/mouse) ,观察抗原激发后反应的变化。结果　 (1)小鼠气道内应用IL 12重组腺病毒在肺内可有效表达 ,48h血浆及肺泡灌洗液IL 12分别为 (5 40± 6 0 )U/ml和 (470 0± 80 0 )U/ml,对照病毒和PBS组未检出 ,两组比较差异有显著性 (P <0 0 1)。 (2 )在抗原激发阶段使用IL 12重组腺病毒 ,可明显抑制肺内IL 4[(3 5± 2 0 )ng/ml∶85 0± 2 5 0 )ng/ml]和IL 5[(6 5± 4 5 )ng/ml∶(5 4 0± 14 0 )ng/ml];γ干扰素 (IFN γ)的产生增加 [(6 90 0± 32 0 )ng/ml∶(12 5±3 2 )ng/ml];并明显抑制气道高反应性 [(36 0± 30 )cmH2 O∶(810± 5 0 )cmH2 O];抑制外周血 [(0 7±0 1) %∶(9 2± 0 5 ) % ]及肺泡灌洗液 [(3 5± 0 7)∶(2 1 6± 4 7)× 10 4 /ml]中的嗜酸细胞的水平 ;与对照组比较 (t分别 =7 97、7 92、5 1 6、18 9、9 33、47 1,P均 <0 0 1) ;但与总IgE[(6 5± 9) μg/ml∶(6 7± 10 )μg/ml]及抗原特异性IgE[(32± 8)∶(33± 8)U/ml]比较无明显影响 (P均 >0 0 5 )。     

Immunoreactive thyroglobulin in sera and saliva of patients with various thyroid disorders: role of autoantibodies

The present study was designed to assess the transfer of thyroglobulin (Tg) and anti-Tg antibodies (TgAb) to saliva in subjects with positive TgAb in their sera. Group I consisted of normal euthyroid control subjects (n = 10). Group II were patients with various thyroid disorders and no TgAb in their sera (n = 6). Group III were patients with thyroid disorders and TgAb in their sera (n = 31). The mean serum Tg level (+/- SE) and mean TgAb level [mean % binding +/- SE (range)] were as follows: Group I, Tg: 22.0 ng/ml +/- 1.64 (n = 10); TgAb 1.91% +/- 0.34 (range 0.6% to 4%). Group II, Tg: 119.8 ng/ml +/- 28.0 (n = 6) TgAb 1.59% +/- 0.34 (0.64% to 2.7%). Group III Tg 167.9 ng/ml +/- 41.0 (n = 31) TgAb 23.2% +/- 3.87 (4.2% to 67.5%). The mean salivary Tg level (SaTg) and mean TgAb binding (% +/- SE range) in saliva were as follows: Group I SaTg 2.07 ng/ml +/- 0.39 (n = 10) SaTgAb 1.13% +/- 0.38 (0% to 3.1). Group II SaTg 3.41 ng/ml +/- 0.67 (n = 6), SaTgAb 0.55% +/- 0.29 (0-1.9%). Group III SaTg 5.22 ng/ml +/- 0.96 (n = 31), SaTgAb 3.1% +/- 1.58 (0 to 47.7%). Salivary TgAb were only present in 4 out of 31 cases of Group III. Mean serum Tg in group IV-A was 75.01 ng/ml +/- 52.1 (n = 11). Mean serum TgAb in group IV-A was 1.94% +/- 0.31 (n = 11).(ABSTRACT TRUNCATED AT 250 WORDS)     

高碳酸血症对急性肺损伤保护作用及机制探讨的实验研究

目的探讨高碳酸血症对急性肺损伤模型的保护作用及可能的机制。方法24只新西兰兔按随机数字表法分为对照组、治疗组、预防组，每组8只。采用脂多糖静脉注射复制肺损伤模型，观察3组兔血流动力学、血气指标的变化；检测肺组织湿／干重（W／D）比、光镜、肺损伤组织学定量评价指标（IQA）来评估肺脏的损伤程度。通过对肺组织中髓过氧化物酶（MPO）、丙二醛（MDA）及血清和支气管肺泡灌洗液（BALF）中白细胞介素-8（IL-8）、肿瘤坏死因子-α（TNF—α）浓度及中性粒细胞凋亡率的测定，阐明高碳酸血症对肺损伤保护的可能机制。结果（1）治疗组、预防组在模型形成后平均动脉压、心率、动脉血二氧化碳分压（PaCO2）、动脉血氧分压／吸入气氧浓度（PaO2／FiO2）分别为（79±6）mm Hg（1mmHg=0．133kPa）、（180±10）次／min、（99±13）mmHg、250±26，（80±9）mmHg、（181±12）次／min、（95±11）mmHg、241±56，与对照组[（66±10）mmHg、（139±13）次／min、（31±4）mmHg、182±35]比较差异有统计学意义（t值分别为4．05、26．32、5．36、28．15、12．54、11．07、16．13、12．36。P均分别〈0．05、0．01）；（2）治疗组、预防组W／D、NPO、MDA分别为1．98±0．28、1．87±0．30、（6．1±1．6）U／g、（5．8±1．5）U／g、（20±5）mg／L、（19±4）mg／L，与对照组[2．43±0．26、（9．0±1．3）U／g、（36±8）mg／L]比较差异有统计学意义（t值分别为11．07、24．46、2．35、9．63，12．34、25．32，P分别〈0．05、0．01）；（3）治疗组、预防组血清和BALF中IL-8、TNF—α、中性粒细胞凋亡率分别为（50±8）ng／ml、（103±49）ng／ml、（94±16）ng／ml、（44±9）ng／ml、（38±9）％、（56±5）％、（49±7）ng／ml、（96±50）ng／ml、（91±14）ng／ml、（39±6）ng／ml、（39±10）％、（55±10）％，与对照组[（91±43）ng／ml、（177±60）ng／ml、（162±15）ng／ml、（67±7）ng／ml、（19±7）％、（43±7）％]比较差异有统计学意义（t值分别为7．12、5．55、7．30、3．93、13．08、8．00，P分别〈0．05、0．01）；（4）各组血清及BALF中IL-8、TNF—α与中性粒细胞凋亡率呈负相关（r值分别为-0．73、-0．72、-0．52、-0．64、-0．73、-0．56、-0．57、-0．78、-0．69、-0．75、-0．82、-0．84，P均〈0．05）。结论高碳酸血症对急性肺损伤具有保护作用，对血流动力学无明显影响。     

Clinical validation of fiberoptic immunobiosensor for point-of-care analysis of plasma nerve growth factor

BACKGROUND: Upregulation of plasma nerve growth factor (NGF) is indicative of cardiac nerve sprouting that is underlying the mechanisms for cardiac arrhythmias. A conventional assay method (e.g., enzyme-linked immunosorbent assay [ELISA]) is usually time consuming and technically complicated for NGF analysis for potential arrhythmia prognosis. OBJECTIVE: This study is to develop a rapid and and reliable assay method for point-of-care (POC) testing of plasma NGF. METHODS: We recently developed a fiberoptic immunobiosensor for point-of-care testing of human plasma NGF. Physiological concentrations of NGF (1 to 200 ng/ml) could be quantified in both buffer and human blood plasma samples (100 microl) within 5 min. The intra-assay coefficient of variation was 5%, and the interassay coefficient of variation was 8%. The clinical utility of the NGF biosensor was evaluated using clinical blood samples from atrial fibrillation patients (n = 21). Peripheral venous blood was sampled before and immediately after radiofrequency ablation and again at postoperative day 1. RESULTS: The NGF level did not change significantly between before (15.73 +/- 16.67 ng/ml) and immediately after radiofrequency ablation (13.58 +/- 11.45 ng/ml, P = NS); however, there was a significant elevation to 28.41 +/- 19.52 ng/ml in postoperative day 1 (P <.01). In a follow-up study (11 +/- 1 months), the increased magnitude in patients with atrial fibrillation recurrence (4.1-fold +/- 1.96-fold) was significantly higher than those without (1.72-fold +/- 0.53-fold; P <.001). The results were highly comparable to those of the ELISA analysis. CONCLUSION: Because of the comparable data accuracy and much faster assay time as compared with ELISA, the fiberoptic biosensor is promising as a clinical POC assay method for plasma NGF analysis at patient bedsides for potential cardiac disease diagnosis and prognosis.